170 related articles for article (PubMed ID: 31141195)
1. Population pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virus-infected children in relation to treatment outcomes.
Archary M; Mcllleron H; Bobat R; LaRussa P; Sibaya T; Wiesner L; Hennig S
Br J Clin Pharmacol; 2019 Sep; 85(9):2066-2075. PubMed ID: 31141195
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
Musiime V; Kendall L; Bakeera-Kitaka S; Snowden WB; Odongo F; Thomason M; Musoke P; Adkison K; Burger D; Mugyenyi P; Kekitiinwa A; Gibb DM; Walker AS;
Antivir Ther; 2010; 15(8):1115-24. PubMed ID: 21149918
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of Lopinavir in Severely Malnourished HIV-infected Children and the Effect on Treatment Outcomes.
Archary M; Mcllleron H; Bobat R; La Russa P; Sibaya T; Wiesner L; Hennig S
Pediatr Infect Dis J; 2018 Apr; 37(4):349-355. PubMed ID: 29227461
[TBL] [Abstract][Full Text] [Related]
4. Once vs twice-daily abacavir and lamivudine in African children.
Musiime V; Kasirye P; Naidoo-James B; Nahirya-Ntege P; Mhute T; Cook A; Mugarura L; Munjoma M; Thoofer NK; Ndashimye E; Nankya I; Spyer MJ; Thomason MJ; Snowden W; Gibb DM; Walker AS;
AIDS; 2016 Jul; 30(11):1761-70. PubMed ID: 27064996
[TBL] [Abstract][Full Text] [Related]
5. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection.
Wang LH; Chittick GE; McDowell JA
Antimicrob Agents Chemother; 1999 Jul; 43(7):1708-15. PubMed ID: 10390227
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.
Zhao W; Cella M; Della Pasqua O; Burger D; Jacqz-Aigrain E;
Br J Clin Pharmacol; 2012 Apr; 73(4):641-50. PubMed ID: 21988586
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study.
Brooks KM; Kiser JJ; Ziemba L; Ward S; Rani Y; Cressey TR; Masheto GR; Cassim H; Deville JG; Ponatshego PL; Patel F; Aurpibul L; Barnabas SL; Mustich I; Coletti A; Heckman B; Krotje C; Lojacono M; Yin DE; Townley E; Moye J; Majji S; Acosta EP; Ryan K; Chandasana H; Brothers CH; Buchanan AM; Rabie H; Flynn PM;
Lancet HIV; 2023 Aug; 10(8):e506-e517. PubMed ID: 37541705
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.
Paediatric European Network for Treatment of AIDS (PENTA)
Antivir Ther; 2010; 15(3):297-305. PubMed ID: 20516550
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team.
Kline MW; Blanchard S; Fletcher CV; Shenep JL; McKinney RE; Brundage RC; Culnane M; Van Dyke RB; Dankner WM; Kovacs A; McDowell JA; Hetherington S
Pediatrics; 1999 Apr; 103(4):e47. PubMed ID: 10103339
[TBL] [Abstract][Full Text] [Related]
10. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Martínez E; Arranz JA; Podzamczer D; Loncá M; Sanz J; Barragán P; Ribera E; Knobel H; Roca V; Gutiérrez F; Blanco JL; Mallolas J; Llibre JM; Clotet B; Dalmau D; Segura F; Arribas JR; Cosín J; Barrufet P; Casas E; Ferrer E; Curran A; González A; Pich J; Cruceta A; Arnaiz JA; Miró JM; Gatell JM;
J Acquir Immune Defic Syndr; 2009 Jul; 51(3):290-7. PubMed ID: 19398921
[TBL] [Abstract][Full Text] [Related]
11. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
Munderi P; Walker AS; Kityo C; Babiker AG; Ssali F; Reid A; Darbyshire JH; Grosskurth H; Mugyenyi P; Gibb DM; Gilks CF;
HIV Med; 2010 May; 11(5):334-44. PubMed ID: 20136661
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M
Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061
[TBL] [Abstract][Full Text] [Related]
13. Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.
Janssen EJH; Bastiaans DET; Välitalo PAJ; van Rossum AMC; Jacqz-Aigrain E; Lyall H; Knibbe CAJ; Burger DM
Br J Clin Pharmacol; 2017 Jun; 83(6):1287-1297. PubMed ID: 28079918
[TBL] [Abstract][Full Text] [Related]
14. Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.
Yuen GJ; Lou Y; Thompson NF; Otto VR; Allsup TL; Mahony WB; Hutman HW
J Clin Pharmacol; 2001 Mar; 41(3):277-88. PubMed ID: 11269568
[TBL] [Abstract][Full Text] [Related]
15. A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa.
Cassim H; Otwombe K; Lazarus E; Liberty A; Gray GE; Greeff OBW; Violari A
PLoS One; 2017; 12(7):e0180645. PubMed ID: 28686654
[TBL] [Abstract][Full Text] [Related]
16. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.
Rozenbaum W; Katlama C; Massip P; Bentata M; Zucman D; Delfraissy JF; Trepo C; David F; Lanier ER; Vavro C; Mamet JP
Antivir Ther; 2001 Jun; 6(2):135-42. PubMed ID: 11491418
[TBL] [Abstract][Full Text] [Related]
17. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).
Bergshoeff A; Burger D; Verweij C; Farrelly L; Flynn J; Le Prevost M; Walker S; Novelli V; Lyall H; Khoo S; Gibb D;
Antivir Ther; 2005; 10(2):239-46. PubMed ID: 15865218
[TBL] [Abstract][Full Text] [Related]
18. Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.
LePrevost M; Green H; Flynn J; Head S; Clapson M; Lyall H; Novelli V; Farrelly L; Walker AS; Burger DM; Gibb DM;
Pediatr Infect Dis J; 2006 Jun; 25(6):533-7. PubMed ID: 16732152
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
Post FA; Moyle GJ; Stellbrink HJ; Domingo P; Podzamczer D; Fisher M; Norden AG; Cavassini M; Rieger A; Khuong-Josses MA; Branco T; Pearce HC; Givens N; Vavro C; Lim ML
J Acquir Immune Defic Syndr; 2010 Sep; 55(1):49-57. PubMed ID: 20431394
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
